Teva Pharmaceutical Industries Ltd. agreed to buy Mexican drugmaker Representaciones e Investigaciones Médicas SA and some assets for $2.3 billion, furthering the Israeli company’s goal of expanding in emerging markets.

Rimsa, which had revenue of $227 million in 2014, will add to earnings from the first quarter of 2017, Petach Tikva, Israel-based Teva said in a statement on Thursday. The transaction will be completed in the early part of next year.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.